MCRB · Seres Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $358.0K | - | $351.0K | - | - | - | - | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $13.20M | - | $12.62M | $12.94M | $11.82M | - | $16.46M | $17.88M | $21.70M | - |
| SG&A | $8.07M | - | $9.48M | $10.25M | $11.89M | - | $12.71M | $16.06M | $15.47M | - |
| Total Operating Expenses | $21.27M | - | $22.83M | $24.88M | $27.24M | - | $29.17M | $31.34M | $39.59M | - |
| D&A | $781.0K | - | $1.04M | $1.06M | $1.08M | - | $1.40M | $1.42M | $1.56M | - |
| Operating Income | ($20.91M) | - | ($22.48M) | ($24.88M) | ($27.24M) | - | ($29.17M) | ($31.34M) | ($39.59M) | - |
| Interest Expense | - | - | - | $0 | $0 | - | $0 | $3.45M | $4.66M | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($19.91M) | - | $8.20M | ($19.86M) | $32.68M | - | $88.78M | ($32.87M) | ($40.13M) | - |
| EPS - Basic | ($2.08) | - | $0.94 | ($2.27) | $3.76 | - | $11.60 | ($4.40) | ($5.40) | - |
| EPS - Diluted | ($2.08) | - | $0.94 | ($2.27) | $3.75 | - | $11.60 | ($4.40) | ($5.40) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.83M | $45.77M | $47.64M | $45.38M | $58.85M | $30.79M | $66.82M | $71.23M | $111.18M | $127.97M |
| Accounts Receivable | $233.0K | $157.0K | $0 | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | $53.00M | $41.97M | $29.65M |
| Accounts Payable | $2.34M | $1.68M | $1.68M | $2.20M | $2.17M | $4.08M | $8.25M | $4.81M | $5.22M | $3.64M |
| Current Assets | $31.84M | $49.38M | $51.53M | $48.69M | $66.08M | $38.67M | $72.93M | $149.26M | $165.18M | $175.41M |
| Total Assets | $117.62M | $138.19M | $143.47M | $143.80M | $164.18M | $139.81M | $178.74M | $321.73M | $341.26M | $358.60M |
| Current Liabilities | $19.34M | $19.32M | $22.43M | $30.94M | $31.32M | $41.22M | $64.83M | $108.28M | $98.48M | $98.66M |
| Long-term Debt | - | - | - | - | - | - | - | $110.00M | $110.00M | $110.00M |
| Total Liabilities | $91.12M | $93.97M | $99.78M | $110.85M | $113.72M | $126.03M | $154.82M | $408.81M | $401.00M | $403.46M |
| Stockholders' Equity | $26.50M | $44.22M | $43.70M | $32.95M | $50.47M | $13.78M | $23.92M | ($87.07M) | ($59.74M) | ($44.86M) |
| Retained Earnings | ($992.32M) | ($972.40M) | ($957.07M) | ($965.27M) | ($945.42M) | ($978.10M) | ($962.46M) | ($1.05B) | ($1.02B) | ($978.24M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.36M) | - | - | - | $26.91M | - | - | - | ($35.24M) | - |
| Investing Cash Flow | $0 | - | - | - | ($34.0K) | - | - | - | ($62.0K) | - |
| Financing Cash Flow | $428.0K | - | - | - | $1.18M | - | - | - | $18.76M | - |
| CapEx | $0 | - | - | - | $34.0K | - | - | - | $62.0K | - |
| Free Cash Flow | ($16.36M) | - | - | - | $26.88M | - | - | - | ($35.30M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -5839.9% | - | -6403.7% | - | - | - | - | - | - | - |
| EBITDA margin | -5621.8% | - | -6106.3% | - | - | - | - | - | - | - |
| Net margin | -5562.3% | - | 2337.3% | - | - | - | - | - | - | - |
| Free cash flow margin | -4569.8% | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.82 | - | - | - | 0.82 | - | - | - | 0.88 | - |
| R&D / Revenue | 3685.8% | - | 3594.3% | - | - | - | - | - | - | - |
| SG&A / Revenue | 2254.2% | - | 2699.7% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | 0.0% | - | 0.0% | - | 0.0% | - | - | - |
| Return on assets | -16.9% | - | 5.7% | -13.8% | 19.9% | - | 49.7% | -10.2% | -11.8% | - |
| Return on equity | -75.1% | - | 18.8% | -60.3% | 64.8% | - | 371.2% | 37.7% | 67.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | -108.0% | -62.2% | - |
| Liquidity | ||||||||||
| Current ratio | 1.65 | 2.56 | 2.30 | 1.57 | 2.11 | 0.94 | 1.12 | 1.38 | 1.68 | 1.78 |
| Quick ratio | 1.65 | 2.56 | 2.30 | 1.57 | 2.11 | 0.94 | 1.12 | 0.89 | 1.25 | 1.48 |
| Cash ratio | 1.54 | 2.37 | 2.12 | 1.47 | 1.88 | 0.75 | 1.03 | 0.66 | 1.13 | 1.30 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | -1.26 | -1.84 | -2.45 |
| Debt / Assets | - | - | - | - | - | - | - | 0.34 | 0.32 | 0.31 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | -9.1x | -8.5x | - |
| Equity multiplier | 4.44 | 3.13 | 3.28 | 4.36 | 3.25 | 10.14 | 7.47 | -3.69 | -5.71 | -7.99 |
| Liabilities / Assets | 0.77 | 0.68 | 0.70 | 0.77 | 0.69 | 0.90 | 0.87 | 1.27 | 1.18 | 1.13 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | - | - | - | - | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 238d | - | 0d | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 20.5x | - | 3.7x | - | 1.6x | - | - | - |
| P / B | 3.2x | - | 3.9x | 2.9x | 2.4x | - | 120.7x | - | - | - |
| P / S | 237.4x | - | 480.8x | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | -100.0% | -100.0% | - |
| Revenue CAGR (3y) | - | - | -53.3% | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | -42.5% | - | -24.4% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 23.2% | - | 22.9% | 20.6% | 31.2% | - | 38.5% | - | 43.9% | - |
| Net income growth (YoY) | - | - | -90.8% | 39.6% | - | - | - | - | 43.6% | - |
| EPS growth (YoY) | - | - | -91.9% | 48.4% | - | - | - | - | -785.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 56.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -47.5% | 220.8% | 82.7% | - | - | - | - | - | -24.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$1.98M totalService$1.98M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Seres Therapeutics against the 5 most active filers in the same SIC group.